Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

But researchers find an increased risk for unvaccinated people infected with SARS-CoV-2.

Covid and neurological disorders © SHUTTERSTOCK

Research, published in the BMJ, found no evidence that COVID-19 vaccines cause immune-mediated neurological disorders such as Bell's palsy (facial weakness), encephalomyelitis (inflammation of the brain and spinal cord), and Guillain-Barré syndrome (a nerve condition). But rates for these conditions were higher than otherwise expected for unvaccinated people infected with SARS-CoV-2.

The COVID-19 pandemic has caused more than 5.5 million deaths worldwide and rising. But a global research effort led to new vaccines being developed and approved, and to date over 9 billion doses have been administered worldwide.

As with all medicines the potential for adverse side effects exists, and recently concerns had been raised regarding cases of immune-mediated neurological disorders following vaccination.

Daniel Prieto-Alhambra, Professor of Pharmaco- and Device Epidemiology at NDORMS led an international team to look for any link. "Reports of Guillain-Barré Syndrome (GBS) cases following the use of some vaccines led to the EMA (European Medicines Agency) listing GBS as a very rare side effect. Cases of Bell's palsy, encephalomyelitis, and transverse myelitis have also been reported following vaccination so large-scale epidemiologic studies like ours are required to determine whether COVID-19 vaccination increases the risks above background rates in the general population."

The study used primary care records from the United Kingdom (UK) and primary care with linked hospital records from Spain to explore the potential link between COVID-19 vaccines and SARS-CoV-2 infection with the risk of developing either of the outcomes; Bell's palsy (facial weakness), encephalomyelitis (inflammation of the brain and spinal cord), Guillain-Barré syndrome (a nerve condition), and transverse myelitis (inflammation of the spinal cord).

Data from over 8 million recipients of the EMA approved Pfizer-BioNtech, Moderna, Oxford–AstraZeneca, Janssen, and Novavax vaccines were analysed. The incidence rates of each of the neurological outcomes in the vaccinated cohorts and SARS-CoV-2-infected cohorts were measured and compared with the "expected" rates of these conditions typically seen in the general population (based on data from more than 14 million people from between 2017 and 2019).

"We didn't see an association between the COVID-19 vaccines and the onset of the neurological conditions in the study." said Daniel. "However, we did observe an increased risk of Bell's Palsy, and encephalomyelitis in unvaccinated patients who had been infected with COVID-19. This underlines the safety of the vaccines being used against COVID-19 and the numerous ill-effects of being infected by SARS-CoV-2 for those people that remain unvaccinated."

Similar stories

Yoshi Itoh wins the International Dupuytren Award 2022

Yoshi Itoh, Associate Professor and Principal Investigator Cell Migration Group at the Kennedy Institute has been awarded the International Dupuytren Award 2022.

Taking a break from immune-suppressing medicines doubles the antibody response to COVID-19 booster vaccination

The Oxford Clinical Trials Research Unit (OCTRU) at NDORMS played a key role in the VROOM study which found that pausing immune-suppressing medicines such as methotrexate can increase the response to COVID-19 booster jabs.

Ten Years of Athena Swan in the Medical Sciences Division

2022 marks ten years since the first Athena Swan Bronze applications from the Medical Sciences Division. Ten years later, and all 16 departments in the Division have achieved a Silver Award. We look at NDORMS’ Athena Swan journey.

NDORMS researchers awarded Associate Professor title

The University of Oxford has awarded the title of Associate Professor to Adam Cribbs and Luke Jostins.

Oxford's largest ever study into varicose veins shows need for surgery is linked to genetics

A new international study by Oxford researchers published in Nature Communications, establishes for the first time a critical genetic risk score to predict the likelihood of patients suffering with varicose veins to require surgery, as well as pointing the way towards potential new therapies.

Reflecting on the role of Clinical Director of Trauma and Orthopaedics

In 2021 Professor Andrew Price was appointed Clinical Director of Trauma and Orthopaedics at the Oxford University Hospitals NHS Foundation Trust. After 9 months in post, we find out what the challenges are and what he’s been able to bring to the role.